Flash Finance

Unichem Laboratories LimitedUNICHEMLABCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹510.55
MCap ₹3,595 Cr · P/E 21.6
Unichem Laboratories Limited — Stock analysis & AI research Unichem Laboratories Limited — Seasonality — best & worst months Unichem Laboratories Limited — Technical indicators & charts Unichem Laboratories Limited — Technical setup — score, trend, support & resistance Unichem Laboratories Limited — Live exchange announcements
📋 Low P/E Stocks📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results📋 High Promoter Holding Stocks 📈 Bollinger Squeeze Stocks📈 20-Day Breakdown Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹366 Cr
Sales · Jun 2026
-4.7% YoY
₹21 Cr
Operating Profit · Jun 2026
-19.8% YoY
5.6%
OPM % · Jun 2026
-16.4% YoY
₹6 Cr
Net Profit · Jun 2026
+398.9% YoY
₹0.79
EPS · Jun 2026
+403.8% YoY

📝 Unichem Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Unichem Laboratories Limited reported revenue of ₹366 crore for the quarter ended June 2026 (Q1 FY27), down 4.7% from ₹384 crore in the same quarter last year, and up 2.9% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹6 crore from a net loss of ₹2 crore a year earlier. Earnings per share (EPS) came in at ₹0.79.

Operating profit stood at ₹21 crore — an operating margin (OPM) of 5.6%, compared with 6.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Unichem Laboratories Limited posted revenue of ₹1,412 crore, a decline of 18.6% over FY25, with a net profit of ₹159 crore (down 2.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,394 crore with a net profit of ₹167 crore.

Valuation snapshot

At the current price of ₹510.55, UNICHEMLAB has a market capitalisation of ₹3,595 crore and a trailing P/E of about 21.6.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 15th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 70.22%, foreign institutional investors (FIIs) 2.70%, domestic institutional investors (DIIs) 9.40%, public shareholders 17.68% of Unichem Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹3,595 Cr
Current Price ?
₹510.6
P/E ?
21.59below ind
Industry P/E ?
37.20
P/B ?
1.37
P/S ?
2.58
P/FCF ?
16.64
Enterprise Value ?
₹3,659 Cr
EV/EBITDA ?
87.86
PEG ?
0.90
Earnings Yield ?
-2.1%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹1,394 Cr
OPM ?
3.0%
Profit after tax (TTM) ?
₹167 Cr
EPS (TTM) ?
₹23.65
ROCE ?
0.0%
ROE ?
6.3%
ROA ?
5.4%
Growth
Sales — latest qtr ?
₹366 Cr
PAT — latest qtr ?
₹6 Cr
YoY qtr sales growth ?
-4.7%
YoY qtr profit growth ?
398.9%
Sales growth (3y) ?
10%
Sales growth (5y) ?
5%
Profit growth (3y) ?
24%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹64 Cr
Debt to Equity ?
0.02
Interest Coverage ?
-6.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
70.22%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-13.3%
Return 6 months ?
45.4%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 252310347334362399390437448461384357315356366 -4.7% +2.9%
Operating Profit -42-98-719314064747526811221 -19.8% +72.0%
Other Income 15468107971964-122911017 +293.4% +67.2%
Interest 232422123224241 -33.2% -67.8%
Depreciation 292827272625262628273030302929 -4.1% -1.1%
Profit Before Tax -57-144-16-3169-11521436256-2-38260-117 +494.7% +167.1%
Net Profit -57-144-16-3169-11521434751-2-40216-156 +398.9% +136.9%
EPS -8.11-20.43-2.23-4.389.85-16.333.056.166.667.28-0.26-5.6730.69-2.190.79 +403.8% +136.1%
OPM % -16.7% -2.8% 2.4% -2.2% 5.3% 7.7% 10.3% 14.6% 16.6% 16.3% 6.7% 2.2% 0.3% 3.4% 5.6% -16.4% +64.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,736 Cr ₹1,412 Cr ₹1,394 Cr -18.6%
Operating Profit ₹253 Cr ₹47 Cr ₹42 Cr -81.6%
OPM % 14.60% 3.31% 2.99% -77.3%
NPM % 9.37% 11.27% 11.94% +20.3%
Other Income ₹41 Cr ₹293 Cr ₹306 Cr +619.6%
Depreciation ₹108 Cr ₹119 Cr ₹118 Cr +10.1%
Interest ₹8 Cr ₹12 Cr ₹11 Cr +52.9%
EBIT ₹145 Cr ₹-72 Cr ₹-76 Cr -149.7%
PBT ₹182 Cr ₹209 Cr ₹218 Cr +14.7%
Tax ₹20 Cr ₹-0 Cr ₹2 Cr -102.3%
Net Profit ₹163 Cr ₹159 Cr ₹167 Cr -2.1%
EPS ₹23.15 ₹22.57 ₹23.62 -2.5%
Material Cost ₹615 Cr ₹204 Cr ₹169 Cr -66.8%
Employee Cost ₹216 Cr ₹73 Cr ₹74 Cr -66.2%
Extraordinary Items ₹4 Cr ₹-276 Cr ₹-276 Cr -6988.0%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 14141414 +0.0%
Reserves 2,3702,2812,4462,613 +6.8%
Borrowings 1087012364 -48.0%
Other Liabilities 394477527401 -23.9%
Total Liabilities 2,8862,8423,1093,092 -0.5%
Fixed Assets 1,2361,1651,2751,189 -6.7%
CWIP 14812231100 +222.6%
Investments 41444647 +2.2%
Other Assets 1,4621,5101,7581,755 -0.2%
Total Assets 2,8862,8423,1093,092 -0.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -117-427253 -26.4%
Cash from Investing Activity 24160-133208 +256.4%
Cash from Financing Activity -62-48-5-71 -1320.0%
Net Cash Flow 62-30-65190 +392.3%
Free Cash Flow -153-53-38216 +668.4%
CFO/OP 126%-81%29%104% +258.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 161141157151 -3.8%
Inventory Days 335264267325 +21.7%
Days Payable 170132120124 +3.3%
Cash Conversion Cycle 325274305352 +15.4%
Working Capital Days 254199202248 +22.8%
ROCE % -6%-1%7%-0% -100.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 70.22%70.22%70.22%70.22%70.22% +0.0%
FIIs 0.98%0.99%0.99%1.00%2.70% +170.0%
DIIs 10.92%10.74%10.73%10.63%9.40% -11.6%
Public 17.88%18.04%18.05%18.14%17.68% -2.5%
No. of Shareholders 23,01023,57723,26723,38626,164 +11.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Unichem Laboratories Limited's revenue in Q1 FY27?
Unichem Laboratories Limited reported revenue of ₹366 crore for the quarter ended June 2026 (Q1 FY27), down 4.7% from ₹384 crore in the same quarter last year, and up 2.9% sequentially over the March 2026 quarter.
What was Unichem Laboratories Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹6 crore from a net loss of ₹2 crore a year earlier. Earnings per share (EPS) came in at ₹0.79.
What is UNICHEMLAB's market capitalisation and P/E ratio?
At the current price of ₹510.55, UNICHEMLAB has a market capitalisation of ₹3,595 crore and a trailing P/E of about 21.6.
Who owns Unichem Laboratories Limited? (shareholding pattern)
As of Sep 2026, promoters held 70.22%, foreign institutional investors (FIIs) 2.70%, domestic institutional investors (DIIs) 9.40%, public shareholders 17.68% of Unichem Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI